ARGX · argenx SE
$984.39
+0.04% last session
End-of-day data · close of 2026-09-11
Market cap
$62B
Enterprise value
$1,533B
Trailing P/E
38.2
Forward P/E
25.0
Dividend yield
—
Beta
-0.02
Avg volume
0M
Employees
2K
Daily Change %
0.04%
5 Days Change
-2.99%
10 Days Change
-2.84%
30 Days Change
15.91%
60 Days Change
14.21%
Month to Day Change
-2.55%
Year to Day Change
19.19%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ARGX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-08
Latest call per bank · past 12 months
Morgan Stanley
Overweight$1,250
+27.0% vs priceUBS
Buy$1,400
+42.3% vs priceWells Fargo
Overweight$1,415
+43.8% vs priceRBC Capital
Outperform$1,100
+11.8% vs priceCitigroup
Buy$1,182
+20.1% vs priceBank of America
Buy$1,088
+10.6% vs priceJP Morgan
Overweight$1,100
+11.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-08 | Wedbush | Reiterates | Outperform | $1,150 |
| 2026-09-03 | Wedbush | Reiterates | Outperform | $1,150 |
| 2026-08-31 | Morgan Stanley | Maintains | Overweight | $1,230 → $1,250 |
| 2026-08-26 | UBS | Upgrade | Neutral → Buy | $960 → $1,400 |
| 2026-08-26 | Wells Fargo | Maintains | Overweight | $1,350 → $1,415 |
| 2026-08-18 | Truist Securities | Maintains | Buy | $1,030 → $1,095 |
| 2026-08-18 | Morgan Stanley | Maintains | Overweight | $1,200 → $1,230 |
| 2026-08-18 | RBC Capital | Maintains | Outperform | $1,025 → $1,100 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.6% above the 50-day MA ($932.23).
- Price vs 200-day MA: Trading 16.3% above the 200-day MA ($846.15).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-10.18) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($663.93) and high ($1,058.90).
ARGX Price Chart
Loading chart for ARGX…
Fundamentals
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
ROIV
Roivant Sciences Ltd.
$30B 92.7% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.